57528-64-0

Basic information

• Product Name: N~1~-phenyl-beta-alaninamide(SALTDATA: HCl)
• Synonyms: N~1~-phenyl-beta-alaninamide(SALTDATA: HCl);PropanaMide, 3-aMino-N-phenyl-;3-Amino-N-phenyl-propionamide
• CAS NO: 57528-64-0
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.20438
• Mol File: 57528-64-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N~1~-phenyl-beta-alaninamide(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: N~1~-phenyl-beta-alaninamide(SALTDATA: HCl)(57528-64-0)
• EPA Substance Registry System: N~1~-phenyl-beta-alaninamide(SALTDATA: HCl)(57528-64-0)

Safety Data

• Hazardous Substances Data: 57528-64-0(Hazardous Substances Data)

Usage

General Description

N~1~-phenyl-beta-alaninamide, also known as SALTDATA: HCl, is a chemical compound that consists of a phenyl group attached to a beta-alanine molecule. It is commonly used in the field of pharmaceuticals as an intermediate in the synthesis of various drugs. The compound is typically found in the form of a hydrochloride salt, which enhances its stability and solubility in water. N~1~-phenyl-beta-alaninamide HCl is known for its potential as a central nervous system stimulant and has been studied for its potential use in the treatment of various neurological disorders. Additionally, it is also used in the production of new chemical entities and drug molecules due to its versatility and reactivity in organic synthesis.

Upstream product

• 621-03-4 cyanoacetanilide 
• 4443-34-9 3-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-N-phenylpropanamide 
• 115022-93-0 benzyl (3-oxo-3-(phenylamino)propyl)carbamate 
• 874942-22-0 tert-butyl [3-oxo-3-(phenylamino)propyl]carbamate 
• 62-53-3 aniline 

Downstream Products

• 27824-25-5 (R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-3-(phenylamino)propyl)butanamide 
• 4742-01-2 N-(3-aminopropyl)aniline 

Relevant articles and documents

Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo

Although gastric cancer has become a major public health problem, oral agents applied in clinics for gastric cancer therapy are scarce. Therefore, to explore new oral chemical entities with high efficiency and low toxicity, 41 o-aminobenzamide derivatives based on the scaffolds of MS-275 and SAHA were designed, synthesized, and evaluated for their anti-gastric cancer abilities in vitro and in vivo. Structure-activity relationships were discussed, leading to the identification of compounds F8 (IC50 = 0.28 μM against HGC-27 cell) and T9 (IC50 = 1.84 μM against HGC-27 cell) with improved cytotoxicity, anti-gastric cancer proliferation potency, induction of cell apoptosis and cell cycle arrest ability, inhibition of cell migration and invasion. What is worth mentioning is that compound F8 was more efficient and less toxic than the positive drug capecitabine in vivo on the HGC-27-xenograft model. Meanwhile, compound F8 exhibited suitable pharmacokinetic properties and less acute toxicity (LD50 > 1000 mg/kg). Besides, western blotting analysis, IHC analysis, differentially expressed proteins analysis and ABPP experiment indicated that compound F8 could modulate molecular pathways involved in apoptosis and cell cycle progression. Consequently, compound F8 is a strong candidate for the development of human gastric cancer therapy.

Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors

Matrix metalloproteinases (MMPs) play important roles in many diseases including cancer. With moderate metal-binding affinity, 8-hydroxyquinoline has gained much interest in current drug design and development. Specially, it has been reported that 8-hydroxyquinoline derivatives serve as MMP-2 inhibitors with micromolar IC50 values. In the current study, a series of 8-hydroxyquinoline derivatives were designed and synthesized as new MMP-2 and MMP-9 inhibitors. The most active compounds 5e and 5h not only displayed good inhibitory activities against MMP-2/9 with IC50 at submicromolar level, but also possessed potent anti-proliferative, anti-invasive and anti-angiogenesis activity in A549 cell line. Western blot also revealed that 5e and 5h down-regulate the expression of MMP-2 and MMP-9 in A549 cell line. Moreover, flow cytometry analysis indicated that compound 5e could promote apoptosis of A549 cells in vitro. Molecular docking analysis also revealed favorable binding modes of 5e in the active sites of MMP-2 and MMP-9.

2-[3-[2-[(25)-2-cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl] -1,2,3,4-tetrahydroisoquinoline: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV

Dipeptidyl peptidase IV (DPP-IV) inhibitors are expected to become a new type of antidiabetic drugs. Most known DPP-IV inhibitors often resemble the dipeptide cleavage products, with a proline mimic at the P1 site. As off-target inhibitions of DPP8 and/or DPP9 have shown profound toxicities in the in vivo studies, it is important to develop selective DPP-IV inhibitors for clinical usage. To achieve this, a new class of 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2- oxoethyl]amino]-1-oxopropyl]-based DPP-IV inhibitors was synthesized. SAR studies resulted in a number of DPP-IV inhibitors, having IC50 values of 50 > 100 μM) and DPP-II (IC50 > 30 μM). Compound 21a suppressed the blood glucose elevation after an oral glucose challenge in Wistar rats and also inhibited plasma DPP-IV activity for up to 4 h in BALB/c mice. The results show that compound 21a possesses in vitro and in vivo activities comparable to those of NVP-LAF237 (4), which is in clinical development. 2006 American Chemical Society.